Oncternal Therapeutics, Inc.
ONCT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $785 | $1,490 | $4,315 | $3,375 |
| % Growth | -47.3% | -65.5% | 27.9% | – |
| Cost of Goods Sold | $29,753 | $179 | $169 | $12,000 |
| Gross Profit | -$28,968 | $1,311 | $4,146 | -$8,625 |
| % Margin | -3,690.2% | 88% | 96.1% | -255.6% |
| R&D Expenses | $29,753 | $32,980 | $24,086 | $12,544 |
| G&A Expenses | $12,546 | $13,457 | $11,595 | $8,373 |
| SG&A Expenses | $12,746 | $13,457 | $11,595 | $8,373 |
| Sales & Mktg Exp. | $200 | $0 | $0 | $0 |
| Other Operating Expenses | -$29,753 | -$1,490 | -$4,315 | -$3,375 |
| Operating Expenses | $12,746 | $44,947 | $31,366 | $17,542 |
| Operating Income | -$41,714 | -$44,947 | -$31,366 | -$17,542 |
| % Margin | -5,313.9% | -3,016.6% | -726.9% | -519.8% |
| Other Income/Exp. Net | $2,235 | $777 | $33 | $317 |
| Pre-Tax Income | -$39,479 | -$44,170 | -$31,333 | -$17,225 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$39,479 | -$43,393 | -$31,300 | -$17,209 |
| % Margin | -5,029.2% | -2,912.3% | -725.4% | -509.9% |
| EPS | -13.43 | -16.5 | -1.94 | -0.69 |
| % Growth | 18.6% | -750.5% | -181.2% | – |
| EPS Diluted | -13.43 | -16.5 | -1.94 | -0.69 |
| Weighted Avg Shares Out | 2,940 | 2,630 | 16,113 | 24,762 |
| Weighted Avg Shares Out Dil | 2,940 | 2,630 | 16,113 | 24,762 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,235 | $777 | $33 | $16 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $41,714 | $179 | $169 | $150 |
| EBITDA | $2,235 | -$44,947 | -$31,164 | -$17,392 |
| % Margin | 284.7% | -3,016.6% | -722.2% | -515.3% |